Newron Pharmaceuticals - Key Evenamide readouts on the horizon
Newron is a Swiss Stock Exchange SIX-listed (NWRN) biopharmaceutical company focused on developing novel medicines for diseases of the central...
258 Views
Newron Pharmaceuticals - Positive readout highlights evenamide potential
Newron has announced encouraging interim six-month data from its Phase II trial (study 014/015) of evenamide in 161 patients with...
212 Views
Newron Pharmaceuticals - Crucial upcoming datasets for evenamide
Newron has released its H123 results and presented an overview of its upcoming clinical activities assessing evenamide as a potential treatment for...
113 Views
Newron Pharmaceuticals - Encouraging efficacy data from evenamide trial
Newron has presented new efficacy data from its Phase II evenamide trial (study 014/015) at the CINP World Congress of Neuropsychopharmacology and...
85 Views
Newron Pharmaceuticals - Positive top-line data to support clinical progress
Newron Pharmaceuticals has announced positive top-line results from its Phase II trial (study 014) assessing evenamide, a glutamate modulator, as...
196 Views